Table 3.
Multivariate competing risk regression analysis
| Variable | Adjusted SHR (95% CI) | p-value |
|---|---|---|
| Age | 0.975 (0.906–1.049) | 0.504 |
| Sex | ||
| Male | 1.0 | - |
| Female | 3.512 (0.653–18.885) | 0.143 |
| Skipped region | ||
| 0 | 1.0 | - |
| 1 | 0.157 (0.043–0.563) | 0.17 |
| 2 | 0.048 (0.001–1.441) | 0.08 |
| ≥3 | 0.209 (0.020–2.154) | 0.189 |
| Metastatic region | ||
| Cervical | 1.0 | - |
| Cervicothoracic | 1.560 (0.026–9.270) | 0.831 |
| Thoracic | 2.159 (0.045–10.244) | 0.696 |
| Thoracolumbar | 0.462 (0.003–5.432) | 0.751 |
| Lumbar | 6.330 (0.075–5.331) | 0.415 |
| Lumbosacral | 2.554 (0.050–1.279) | 0.639 |
| Primary tumor | ||
| Lung | 1.0 | - |
| Breast | 0.269 (0.040–1.7903) | 0.175 |
| Renal | 1.827 (0.122–27.253) | 0.662 |
| Prostate | 1.646 (0.169–16.045) | 0.668 |
| Othersa) | 0.059 (0.002–1.435) | 0.082 |
| SINS | 1.302 (0.758–2.237) | 0.338 |
| Lesion type | ||
| Sclerotic | 1.0 | - |
| Lytic | 0.500 (0.040–6.110) | 0.588 |
| Mixed | 0.438 (0.076–2.520) | 0.355 |
| Instrumented region | ||
| Cervicothoracic | 1.0 | - |
| Thoracic | 0.559 (0.024–12.986) | 0.718 |
| Thoracolumbar | 2.688 (0.176–40.955) | 0.477 |
| Lumbar & lumbosacral | 0.906 (0.041–19.567) | 0.95 |
| Construct length | 1.066 (0.816–1.392) | 0.638 |
| ECOG score | ||
| 3–4 (non-ambulatory) | 1.0 | - |
| 0–2 (ambulatory) | 7.021 (1.639–30.078) | 0.0009 |
Bold type is considered as statistically significant. Competing risk regression (multivariate model) with symptomatic failure as event of interest and death as the competing event.
SHR, sub-hazard ratio; CI, confidence interval; SINS, Spinal Instability Neoplastic Score; ECOG, Eastern Cooperative Oncology Group.
a)
Include hematological malignancies (n=30), hepatocellular carcinoma/gastrointestinal tumors (n=27), ovarian (n=7), cervical (n=9), thyroid (n=7), nasopharyngeal (n=10), and others (n=2).